Equities Analysts Offer Predictions for EWTX FY2026 Earnings

Key Points

• HC Wainwright sharply raised its FY2026 EPS estimate for Edgewise Therapeutics to $9.29 from a prior loss estimate of $2.07; the consensus estimate is $5.43. The firm maintained its Buy rating.
• Analysts collectively rate EWTX a Moderate Buy, with an average price target of $52.83. Recent views include JPMorgan’s $60 target and Wedbush’s trimmed $51 target, while retaining an Outperform rating.
• Potential takeover interest has been reported as a near-term catalyst, though no deal is confirmed. Separately, the FDA gave favorable feedback on EDG-7500’s Phase 3 plan, with the STRATUS-HCM trial expected to begin in Q4 2026.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Equities research analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Edgewise Therapeutics in a research report issued on Thursday, November 5th. HC Wainwright analyst L. Egana-Gorrono now anticipates that the company will earn $9.29 per share for the year, up from their previous estimate of ($2.07). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Edgewise Therapeutics' current full-year earnings is $5.43 per share. HC Wainwright also issued estimates for Edgewise Therapeutics' Q4 2026 earnings at ($0.47) EPS and FY2027 earnings at ($2.22) EPS.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $9.65 earnings per share for the quarter, topping the consensus estimate of ($0.53) by $10.18.

A number of other analysts have also recently weighed in on EWTX. The Goldman Sachs Group raised their price objective on shares of Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a "neutral" rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. increased their target price on shares of Edgewise Therapeutics from $53.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, August 20th. Wedbush reduced their price target on shares of Edgewise Therapeutics from $53.00 to $51.00 and set an "outperform" rating for the company in a research report on Thursday. William Blair began coverage on shares of Edgewise Therapeutics in a research note on Friday, October 16th. They issued an "outperform" rating for the company. Finally, Raymond James Financial restated an "underperform" rating and issued a $85.00 price objective on shares of Edgewise Therapeutics in a research note on Thursday. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $52.83.

Edgewise Therapeutics Price Performance

Shares of EWTX opened at $45.04 on Monday. The company has a market capitalization of $4.93 billion, a price-to-earnings ratio of 5.50 and a beta of 0.39. Edgewise Therapeutics has a 52-week low of $16.70 and a 52-week high of $48.51. The stock has a 50 day moving average price of $40.86 and a 200 day moving average price of $36.54.

Institutional Trading of Edgewise Therapeutics

Several hedge funds have recently made changes to their positions in EWTX. Parallel Advisors LLC raised its holdings in Edgewise Therapeutics by 64.9% during the first quarter. Parallel Advisors LLC now owns 1,032 shares of the company's stock worth $33,000 after purchasing an additional 406 shares in the last quarter. KBC Group NV acquired a new stake in Edgewise Therapeutics in the first quarter valued at about $49,000. Sterling Capital Management LLC boosted its holdings in Edgewise Therapeutics by 840.2% in the 3rd quarter. Sterling Capital Management LLC now owns 2,360 shares of the company's stock valued at $96,000 after purchasing an additional 2,109 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Edgewise Therapeutics by 26.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,666 shares of the company's stock valued at $108,000 after purchasing an additional 559 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Edgewise Therapeutics during the 3rd quarter worth approximately $225,000.

Insider Buying and Selling

In related news, CMO Joanne M. Donovan sold 6,522 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $43.85, for a total transaction of $285,989.70. Following the completion of the sale, the chief marketing officer directly owned 11,544 shares of the company's stock, valued at $506,204.40. This trade represents a 36.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel John Moore sold 5,016 shares of Edgewise Therapeutics stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $43.82, for a total transaction of $219,801.12. Following the completion of the transaction, the general counsel owned 17,697 shares in the company, valued at approximately $775,482.54. This trade represents a 22.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 38,329 shares of company stock worth $1,675,529. Corporate insiders own 21.30% of the company's stock.

Key Stories Impacting Edgewise Therapeutics

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: A report of takeover interest appears to be the main near-term catalyst behind the stock’s rise. The report does not establish that a deal has been agreed or that a transaction will occur. Edgewise Therapeutics gains amid report of takeover interest
• Positive Sentiment: The FDA gave favorable feedback on EDG-7500’s Phase 3 plan following an end-of-Phase 2 meeting. The STRATUS-HCM program is designed to study obstructive and nonobstructive HCM and is on track to begin in Q4 2026, reducing uncertainty around the development path. FDA meeting and Phase 3 update
• Neutral Sentiment: Wedbush cut its price target to $51 from $53 but kept an Outperform rating, leaving its view positive despite the modest reduction. Wedbush lowers EWTX price target
• Neutral Sentiment: Edgewise reported quarterly EPS of $9.65, well above the consensus estimate of a loss of $0.53. The unusually large reported figure may need context to assess its relevance to ongoing operations.
• Negative Sentiment: Put-option purchases were unusually high, with 2,813 contracts traded—279% above typical volume. This may reflect increased hedging or bearish positioning, though options activity alone does not confirm investor expectations.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions.

Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.